Survodutide

Survodutide combines glucagon and GLP-1 receptor activity. Research explores weight regulation and metabolic outcomes; the cited phase II findings provide context for its potential rather than a prediction for an individual.

Research focus & potential applications

Dual-receptor signaling

Weight regulation

What the research shows

Explore the selected studies, their findings and their limits.

Read the findings & sources

Human study discussed

A 46-week phase II trial in adults with overweight or obesity without diabetes found mean weight reduction of 14.9% in the highest planned-treatment group, versus 2.8% with placebo. Gastrointestinal events were the most frequent adverse effects. This was a dose-finding trial of combined glucagon and GLP-1 receptor activity; its results cannot establish superiority over medicines tested in different populations or trials.

PubMed · 38330987

For more information, contact info@aurevixpeptides.com.

Editorial review: September 23, 2026